Valuation: Abpro Holdings, Inc.

Market Cap 1.29M 1.12M 1.04M 954K 1.81M 124M 1.84M 12.4M 4.87M 60.52M 4.83M 4.72M 209M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 1.37M 1.19M 1.1M 1.01M 1.92M 132M 1.95M 13.17M 5.17M 64.28M 5.13M 5.02M 222M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
1 day-8.31%
Current month-96.53%
Current year-96.53%
3 years 0.19
Extreme 0.1946
13
5 years 0
Extreme 0
13
10 years 0
Extreme 0
13
Date Insider Type Main position Quantity % Market Cap.
4/18/23 Fiscal year

Director

50,000 0.7663%
4/18/23 Fiscal year

Director

50,000 0.7663%
4/18/23 Fiscal year

Director

50,000 0.7663%
Change 5-day change 1-year change 3-year change Capi.($)
-8.31%+12.78% - - 1.29M
-1.07%+0.38%+2.06%+5.66% 50.35B
-2.85%-6.25%+366.61%+573.36% 39.21B
+1.78%+0.73%+32.68%-4.91% 34.52B
+1.98%+4.82%+13.71%+60.39% 34.6B
+0.06%-0.57%+3.35%+27.42% 27.05B
-3.27%-5.67% - - 16.68B
+1.64%+0.45%+70.86%+117.46% 15.11B
+0.29%+3.64%+15.30%+17.80% 13.85B
-1.21%+0.73%+18.02%-30.62% 13.18B
Average -1.18%+0.81%+65.32%+95.82% 27.17B
Weighted average by Cap. -0.46%+0.70%+77.64%+118.69%

Financials

2024 2025
Net sales 183K 160K 148K 136K 257K 17.63M 261K 1.76M 693K 8.61M 687K 672K 29.73M -
Net income -7.23M -6.32M -5.85M -5.36M -10.15M -697M -10.33M -69.72M -27.39M -340M -27.16M -26.56M -1.17B -2.89M -2.53M -2.34M -2.15M -4.06M -279M -4.13M -27.88M -10.95M -136M -10.86M -10.62M -470M
Net Debt 478K 418K 386K 355K 671K 46.06M 683K 4.61M 1.81M 22.49M 1.8M 1.76M 77.65M 80K 69.93K 64.67K 59.34K 112K 7.71M 114K 771K 303K 3.76M 300K 294K 13M
Logo Abpro Holdings, Inc.
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
2
Date Price Change Volume
26-07-16 US$0.2000 -8.31% 3,991
26-07-15 US$0.2181 +6.56% 12,007
26-07-14 US$0.2047 +2.86% 6,646
26-07-13 US$0.1990 -10.36% 3,152
26-07-10 US$0.2220 +14.73% 5,455

Quarterly revenue - Rate of surprise